Study of Provent Treatment of Obstructive Sleep Apnea in Patients Who Are Non-compliant With CPAP
This study has been completed.
Sponsor:
St. Luke's Hospital, Chesterfield, Missouri
Collaborator:
Ventus Medical, Inc.
Information provided by:
St. Luke's Hospital, Chesterfield, Missouri
ClinicalTrials.gov Identifier:
NCT00901771
First received: May 13, 2009
Last updated: June 14, 2010
Last verified: June 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of the proposed investigation is to evaluate the efficacy of the Provent device in a sample of OSA patients who have either refused or been non-adherent with PAP treatment. Both initial efficacy (evaluated after approximately one week with Provent) and efficacy after approximately 5 weeks in patients who demonstrate initial efficacy will be assessed. A secondary objective is to assess adherence with Provent treatment during the 5-week evaluation period.
| Condition | Intervention |
|---|---|
|
Sleep Apnea, Obstructive |
Device: Provent |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Non-randomized, Case Series Study of the Effectiveness of Provent Treatment of Obstructive Sleep Apnea Patients Who Are Non-compliant or Minimally Adherent With Positive Airway Pressure Therapy |
Resource links provided by NLM:
Further study details as provided by St. Luke's Hospital, Chesterfield, Missouri:
Primary Outcome Measures:
- Week 1 AHI as compared to Screening/Baseline AHI [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Week 5 AHI as compared to Screening/Baseline AHI [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
- Minutes with SaO2 <90%: Week 5 vs. Screening/Baseline [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
- Epworth Sleepiness Scale: Week 5 vs. Baseline [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | May 2009 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Device: Provent
This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Current signs and symptoms consistent with a diagnosis of OSA in the opinion of the study physician
- Rejection of PAP treatment or minimally adherent with PAP treatment
- Use of the Provent device for a specified amount of time each night during three consecutive nights of the trial period
- AHI > 15, or AHI > 10 with evidence of CMS-recognized symptoms or co- morbidities, on screening/baseline PSG
- Investigator believes that subject can benefit from OSA treatment
- Subject understands and is willing and able to comply with study requirements
Exclusion Criteria:
- Use of any device that interferes with nasal or oral breathing
- Persistent blockage of one or both nostrils which prevents airflow in one or both nostrils
- Any chronic sores or lesions on the inside or outside of the nose
- Chronic use of nasal decongestants other than nasal steroids
- History of allergic reaction to acrylic-based adhesives (such as those found in BAND-AIDS®)
- Current acute upper respiratory (including nasal, sinus, or middle ear) inflammation or infection or perforation of the tympanic membrane (may be re-considered for participation after the acute episode resolves)
- History of frequent and/or poorly treated severe nasal allergies or sinusitis which may interfere with the ability to use Provent
- Severe respiratory disorders (including respiratory muscle weakness, bullous lung disease, bypassed upper airway, pneumothorax, pneumomediastinum, etc.).
- Pathologically low blood pressure.
- Narcolepsy, idiopathic hypersomnolence, chronic insomnia, restless legs syndrome, REM sleep behavior disorder or any other diagnosed or suspected sleep disorder other than OSA that could affect the likelihood of apneas/hypopneas during a PSG.
- Periodic limb movement arousal index (PLMAI) > 10 on the screening/baseline PSG.
- Current use of diurnal or nocturnal supplemental oxygen
- Currently working night or rotating shifts
- Consumption of > 10 caffeinated beverages per day (approximately 1000 mg per day)
- History of severe cardiovascular disease, including New York Heart Association Class III or IV heart failure, coronary artery disease with angina or myocardial infarction in the past 6 months, stroke in the past 6 months
- History of cardiac rhythm disturbance (defined as a 5-beat run of sustained ventricular tachycardia or bradycardia if < 30 beats per min for a 10-second run or previously undiagnosed and untreated atrial fibrillation or Mobitz II or third-degree heart block)
- Current psychiatric disorder with psychotic features.
- Pregnant or trying to become pregnant
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00901771
Locations
| United States, Missouri | |
| Sleep Medicine and Research Center at St. Luke's Hospital | |
| Chesterfield, Missouri, United States, 63017 | |
Sponsors and Collaborators
St. Luke's Hospital, Chesterfield, Missouri
Ventus Medical, Inc.
Investigators
| Principal Investigator: | James K Walsh, Ph.D. | Sleep Medicine and Research Center at St. Luke's Hospital |
More Information
No publications provided
| Responsible Party: | James K. Walsh, Ph.D., Sleep Medicine and Research Center at St. Luke's Hospital |
| ClinicalTrials.gov Identifier: | NCT00901771 History of Changes |
| Other Study ID Numbers: | Ventus C020 |
| Study First Received: | May 13, 2009 |
| Last Updated: | June 14, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by St. Luke's Hospital, Chesterfield, Missouri:
|
Sleep Sleep Apnea, Obstructive OSA OSAH |
Additional relevant MeSH terms:
|
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013